For example, it has been reported that when glioma-bearing rats were treated with genetically modified IL-2 expressing MSCs, the proliferative capacity of the cells was remarkably mitigated, suggesting that the delivered IL-2 into the TME could enhance the cytotoxic immune responses against malignant cells (178). The gene discussed is IL2; the disease is glioma.